[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronavirus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronavirus":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,48,78,100,130,159,189,221,240],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100421774","observational-digital-biomarker-discovery-in-respiratory-virus-challenge-studies-100421774",false,"NCT04772170","Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Able to provide informed consent.\n2. Current, recent, or planned enrollment in a respiratory virus challenge study at the NIH Clinical Center.\n3. Willing to wear devices as instructed.\n4. Willing to participate in monitoring activities as instructed.\n5. Willing to have monitoring data stored.\n6. Willing to have monitoring data shared with protocol investigators at NIH, University of Washington, and University of Toronto.\n7. Willing to have select clinical data from the challenge study such as vital signs, viral shedding, pulmonary function test and\u002For spirometry results, and clinical symptoms data shared with investigators at University of Washington and University of Toronto.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1\\. Any condition that, in the opinion of the investigator, contraindicates participation in this study.\n\nCo-enrollment guidelines: Participants must be co-enrolled, planned for co-enrollment, or recently enrolled in a challenge study. Co-enrollment in other studies is restricted but may take place after study staff notification and only with approval of the principal investigator or designee.",true,"ALL","18 Years","65 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","Background:\n\nRespiratory viruses circulate throughout the year and around the globe. Wearable and sensor devices, like smartwatches, may be able to help monitor infectious diseases. Researchers want to use them to learn how respiratory viruses affect people in different ways.\n\nObjective:\n\nTo use digital devices to collect data from participants in challenge studies that could indicate subtle changes in health during an infection that might otherwise go unnoticed.\n\nEligibility:\n\nHealthy adults who have enrolled, were recently enrolled, or are scheduled to enroll in a challenge study.\n\nDesign:\n\nParticipants will stay at NIH for the duration of the challenge study (at least 9 days) and then will have outpatient follow-up visits (2-4).\n\nWhile at NIH, participants will wear a smartwatch at all times. It will record data like temperature, heart rate, breathing rate, and movements.\n\nParticipants will have a smartphone that records at all times to listen for coughing and changes in voice.\n\nParticipants will perform tasks every 4 hours during the daytime. They will record themselves coughing, breathing in deeply, and reading aloud. They will take videos of their face. They will play a game to test their reflexes and focus. They will measure their head temperature with their smartwatch.\n\nFor outpatient visits, participants will use one smartphone and the smartwatch to complete the above tasks.\n\nParticipants will be sent a smartwatch to wear at home at night to collect additional healthy data.\n\nParticipation will last the duration of each challenge study, and may range from 10 weeks to 2 years.",[25,26,27],"Influenza","Respiratory Virus","Coronavirus",[29,30,31,32,33,34],"Wearable Digital Device","Bed Sensor","Smartphone","Cough Count","Smartwatch","Natural History","RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-18","ACTUAL",{"date":41,"type":39},"2023-10-23",{"date":43,"type":21},"2027-06-02",{"name":45,"class":46},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100523752","evaluation-of-concordance-between-exhaled-air-test-ebam-cov-and-rt-pcr-to-detect-sars-cov-2-100523752","NCT06099795","Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2","Evaluation of Concordance Between an Innovative Test on Exhaled Air (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2 in Symptomatic Patients or Closed Contacts","eBAM_CoV","Inclusion Criteria:\n\n* Adult male or female patients over 18 years of age (≥)\n* Suspected of being infected with COVID-19 (symptomatic or contact case) and consulting for RT-PCR screening.\n\nExclusion Criteria:\n\n* Inability to understand the procedures to use the device\n* Patient participating in an another interventional study\n* Patient in exclusion period determined by another study\n* Patient under court protection or guardianship\n* Patient\u002Ftrusted person\u002Flegal representative\u002Ffamily member for whom it is impossible to give informed information.\n* Pregnant, parturient or breast-feeding patient",{"count":57,"type":21},250,"INTERVENTIONAL",[60],"NA","During the COVID-19 pandemic, testing primarily relied on the use of nasopharyngeal swabs to detect the SARS-CoV-2 virus, responsible for the disease. However, this technique has several limitations, including the variable quality of swabs, its invasive nature, and arbitrariness in the choice of the number of cycles. Furthermore, it does not allow for the detection of viral proteins.\n\nTo overcome these limitations, researchers developed the eBAM-CoV test, patented for the detection of viral proteins in the exhaled air of COVID-19 patients. This portable device provides an immediate assessment of the \"viral load\" with both quantitative and qualitative results, showing promise for early virus detection.\n\nThe researchers hypothesize that the eBAM-CoV test is likely to exhibit a satisfactory concordance with the reference RT-PCR test in the detection of COVID-19, especially among symptomatic patients or closed contacts.",[63,64,27],"SARS-CoV-2 Infection","COVID-19",[66],"Diagnostic Test Kits","2026-05-22",{"date":69,"type":39},"2026-05-27",{"date":71,"type":39},"2025-01-01",{"date":73,"type":21},"2027-12",{"name":75,"class":76},"Centre Hospitalier Universitaire de Nīmes","OTHER",2,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":86,"studyType":22,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":47},"100390739","armor-study-covid-19-seroprevalence-among-healthcare-workers-100390739","NCT04367857","ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers","SARS-CoV-2 Seroprevalence Among Healthcare Workers: ARMOR Study Demonstration Project","Inclusion Criteria:\n\n* 18 years of age or older\n* NewYork-Presbyterian (NYP) healthcare personnel employee or affiliate\n* Understands and reads English\n\nExclusion Criteria:\n\n* Younger than 18 years of age\n* Mentally and\u002For physically unable to complete study requirements",{"count":20,"type":21},"1 Year","The novel coronavirus (SARS-CoV-2) has spread all around the world and testing has posed a challenge globally. Health care providers are highly exposed and are an important group to test. On top of these concerns, health care workers are also stressed by the needs on responders in the COVID-19 crisis. The investigators will look at different ways to measure how common COVID-19 is among health care workers, how common is the presence of antibodies by serological tests (also known as serostatus). The investigators will describe health worker mental and emotional well-being and their coping strategies in their institutional settings. Lastly, the investigators will describe how knowing serostatus can affect individuals' mental and emotional well-being and how to cope in the midst of the COVID-19 response. This will help to how to better test and help healthcare workers in the COVID-19 pandemic and prepare for possible future outbreaks.",[89,90,27],"Covid-19","Coronavirus Infection","2026-04-03",{"date":93,"type":39},"2026-04-08",{"date":95,"type":39},"2020-04-18",{"date":97,"type":21},"2027-02",{"name":99,"class":76},"Columbia University",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":129},"100609939","prospective-clinical-evaluation-of-the-biofire-emerging-coronavirus-panel-for-the-detection-of-covid-19-and-other-coronaviruses-100609939","NCT07221097","Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses","Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel - Sponsor's Protocol","Inclusion Criteria:\n\n* Specimen is residual NPS in transport medium (VTM or UTM) left over from standard of care testing under clinician order for respiratory pathogen analysis.\n* Specimen has been held at room temperature for less than or equal to 4 hours or 4°C for less than or equal to 72 hours before enrollment.\n* At least 1.7 mL of specimen is remaining after standard of care testing and available for use in the study\n\nExclusion Criteria:\n\n* Specimen is unable to be tested within the defined storage parameters\n* Insufficient specimen volume for testing\n* Transport medium type is unknown",{"count":108,"type":21},1500,"The Biomedical Advanced Research and Development Authority (BARDA) has contracted BioFire Defense (BFDf) to develop the BioFire Emerging Coronavirus (ECoV) Panel, a nucleic acid test capable of detecting coronaviruses from nasopharyngeal swab (NPS) in transport medium.\n\nThis study aims to evaluate the diagnostic accuracy of the assays comprising the BioFire ECoV Panel. It is hypothesized that the BioFire ECoV Panel assays will be highly sensitive and specific for the detection of the coronaviruses included on the panel.",[27,111,112],"Respiratory Infection","COVID",[114,115,116,117,118],"in vitro diagnostic","pandemic preparedness","medical device","molecular diagnostic","coronavirus","2025-10-23",{"date":121,"type":39},"2025-10-27",{"date":123,"type":39},"2025-09-29",{"date":125,"type":21},"2026-08",{"name":127,"class":128},"BioFire Defense LLC","INDUSTRY",6,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":58,"phases":139,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":158},"100505965","impact-of-aerosol-box-use-during-cardiopulmonary-arrest-a-multicenter-study-100505965","NCT05868239","Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study","Inclusion Criteria:\n\nAirway Provider:\n\n* Attending physician, fellow or resident in adult or pediatric emergency medicine, pediatric intensive care, general pediatrics or pediatric\u002Fadult anesthesia\n* Adult or Pediatric Advanced Life Support certification.\n\nCPR Provider:\n\n* Attending physician, resident, fellow, nurse, respiratory therapist, physician assistant or health care aide\n* Basic Life Support, Adult or Pediatric Advanced Life Support certification\n\nExclusion Criteria:\n\n* Decline to provide informed consent\n* Unable to perform tasks required of the role due to physical limitations.","60 Years",{"count":138,"type":21},240,[60],"Aerosol Generating Medical Procedures (AGMP) are procedures that have the potential to create tiny particles suspended in the air. These particles can contain germs such as viruses. The Coronavirus Disease 2019 (COVID-19) pandemic was caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients infected with SARS-CoV-2 experience unusually high rates of critical illness that needs advanced airway management and intensive care unit admission. Bag-valve-mask (BVM) ventilation, endotracheal Intubation (ETI) and chest compressions are sometimes required for critically ill COVID-19 patients, and may contribute to a high risk of infection amongst Health Care Workers (HCW). To lessen HCW risk during high-risk procedures, a device called an aerosol box has been developed to place over the head of the patient, shielding the provider's face from virus droplets suspended in the air.\n\nThe purpose of this research study is to better understand how particles disperse during AGMPs, more specifically during the provision of cardiopulmonary resuscitation (CPR). The project team hopes what is learned from the project can help inform infection control measures. This could help make changes to the clinical environment and make it safer for HCW's. The investigators intend to explore how an aerosol box performs in reducing contamination of HCW's who perform critical airway interventions during resuscitation events.",[142,64,27],"Cardiac Arrest",[144,145,146,147],"cardiac arrest","simulation","aerosol generating medical procedure","intubation","2025-08-28",{"date":150,"type":39},"2025-09-05",{"date":152,"type":39},"2023-09-01",{"date":154,"type":21},"2026-12-01",{"name":156,"class":157},"KidSIM Simulation Program","NETWORK",4,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":167,"conditions":168,"keywords":176,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":47},"100390125","a-study-to-explore-the-role-of-gut-flora-in-covid-19-infection-100390125","NCT04359836","A Study to Explore the Role of Gut Flora in COVID-19 Infection","A Non-Interventional Pilot Study to Explore the Role of Gut Flora in COVID-19 Infection","Inclusion Criteria:\n\n1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study\n2. Male or female of 18 years of age or older\n3. Diagnosis of COVID-19 infection by RT- PCR within 1 week of Screening\n\nExclusion Criteria:\n\n1. Refusal to sign informed consent form\n2. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.\n3. Postoperative stoma, ostomy, or ileoanal pouch\n4. Treatment with total parenteral nutrition",{"count":57,"type":21},"This study seeks to determine whether the virus which causes COVID-19, SARS-CoV-2, is shed in the stools of patients who are infected.",[169,170,112,64,171,27,172,173,174,175],"Gut Microbiome","Gastrointestinal Microbiome","Corona Virus Infection","Coronaviridae Infections","Coronavirus 19","Coronavirus-19","COVID 19",[177,27,178,179,112,64],"Microbiome","Corona Virus","19","2025-06-02",{"date":182,"type":39},"2025-06-05",{"date":184,"type":39},"2020-04-16",{"date":186,"type":21},"2027-07-31",{"name":188,"class":76},"ProgenaBiome",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":58,"phases":199,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":212,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":219,"locationsCount":77},"100487925","phase-1-next-generation-t-cell-vaccine-against-coronavirus-disease-covid-19-100487925","NCT05633446","Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)","A Phase I-II, Blinded, Randomized, Placebo-controlled Study of a T Cell Priming Next-generation Vaccine Against Coronavirus Disease in Healthy Adults","Inclusion Criteria:\n\n1. Healthy volunteers aged 18 to 75 years on the day of inclusion\n2. Participant signed informed consent\n3. Residing in Philippines.\n4. A participant can be included providing COVID-19 polymerase chain reaction (PCR) test is negative at screening.\n5. A participant can be included providing, the participant haven't received any vaccination against COVID-19 in the past, or if the participant had already received any of the following licensed vaccines against COVID-19: Oxford\u002FAstraZeneca; Pfizer\u002FBioNTech; Moderna; or J\\&J\u002FJanssen, with the participants last dose received at least 6 months prior the inclusion in this trial.\n\nExclusion Criteria:\n\n1. Participant is pregnant, lactating, or of childbearing potential\n2. Participation in the 6 months preceding the first trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure\n3. Receipt of any vaccination against COVID-19 less than 6 months prior to participation in study.\n4. Receipt of any vaccine in the three months preceding the first trial vaccination or planned receipt of any vaccine in the 6 months following last trial vaccination.\n5. Positive SARS-CoV-2 test in the 4 weeks preceding the first trial vaccination\n6. Receipt of immunoglobulins, blood, or blood-derived products in the past 3 months\n7. Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy\n8. Self-reported or documented seropositivity for human immunodeficiency virus (HIV), hepatitis B natural infection (HBcAb positive serology), or hepatitis C\n9. Known systemic hypersensitivity to any of the vaccine components (e.g. gold), or history of a life-threatening reaction to vaccines or to a vaccine containing any of the same substances\n10. Current alcohol abuse or drug addiction (reported or suspected)\n11. Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion\n12. Thrombocytopenia or any coagulation disorder\n13. Identified as an Investigator or employee of the Investigator or study centre with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study (i.e. in the employment of the clinical trial sites).\n14. Refusal to be informed if relevant results concerning the participant's health are revealed","75 Years",{"count":198,"type":21},110,[200,201],"PHASE1","PHASE2","The study aims to investigate the safety and immunogenicity of one dose vs two doses of a T-cell priming next-generation vaccine against Coronavirus disease.",[27,63,64],[27,205,64,206,207,208,209,210,211],"SARS-CoV-2","T-cell priming","COVID vaccine","Nanoparticle","T cell","Cellular immunity","T-cell vaccine","NOT_YET_RECRUITING","2025-02-21",{"date":215,"type":39},"2025-02-24",{"date":217,"type":21},"2025-09-01",{"date":154,"type":21},{"name":220,"class":128},"Gylden Pharma Ltd",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":47},"100387130","risk-factors-for-community--and-workplace-transmission-of-covid-19-100387130","NCT04320732","Risk Factors for Community- and Workplace Transmission of COVID-19","Inclusion Criteria:\n\n* Norwegian adult\n\nExclusion Criteria:\n\n* Unable to consent",{"count":228,"type":21},250000,"The project is an epidemiological observational study based on an electronic questionnaire on risk factors for COVID-19 in the community and healthcare setting.",[27],"2021-11-29",{"date":233,"type":39},"2021-12-13",{"date":235,"type":39},"2020-03-27",{"date":237,"type":21},"2030-03-20",{"name":239,"class":76},"Oslo University Hospital",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":248,"phases":4,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":259,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":263,"locationsCount":4},"100384669","eculizumab-soliris-in-covid-19-infected-patients-100384669","NCT04288713","Eculizumab (Soliris) in Covid-19 Infected Patients","Soliris to Stop Immune Mediated Death In Covid 19 Infected Patients. A Trial of Distal Complement Inhibition.","SOLID-C19","Inclusion Criteria:\n\n* Age 18 or older.\n* Confirmed Covid-19 infection\n* ARDS\n* ICU patient\n\nExclusion Criteria:\n\n* Active Neisseria infection.\n* Concomitant enrollment in another experimental\u002Foff-label immunosuppressive therapy trial.","EXPANDED_ACCESS","Covid-19 has spread rapidly throughout the world causing widespread panic, death, and injury. While this virus is the provocateur, it is often the patient's own disproportionate immune response which deals the most devastating (and often fatal) damage. A specific part of the immune system, known as the complement, has been shown to cause such damage in other types of coronaviruses. In the SOLID-C19 study, Soliris (Eculizumab) will be used to modulate the activity of the distal complement preventing the formation of the membrane attack complex. By modulating this portion of the immune response, mortality can be halted while the patient has time to recover from the virus with supportive medical care.",[27],[252,253,254,89,255,256,257,258,27,178],"Covid19","Soliris","Eculizumab","Complement","Immunomodulation","ARDS","Adult respiratory distress syndrome","AVAILABLE","2020-03-26",{"date":262,"type":39},"2020-03-30",{"name":264,"class":76},"Hudson Medical"]